

# بسم الله الرحمن الرحيم



HOSSAM MAGHRABY



# شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم



HOSSAM MAGHRABY

# جامعة عين شمس

## التوثيق الإلكتروني والميكروفيلم

### قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
على هذه الأقراص المدمجة قد أعدت دون أية تغيرات



## يجب أن


تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HOSSAM MAGHRABY



# بعض الوثائق الأصلية تالفة



HOSSAM MAGHRABY



بالرسالة صفحات

لم ترد بالأصل



HOSSAM MAGHRABY

# **IMMUNOHISTOCHEMICAL ESTIMATION OF PROGESTERONE RECEPTORS IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL CARCINOMA**

## **THESIS**

Submitted for Partial Fulfillment of the M.D. Degree in  
*Pathology*

INVESTIGATOR


**KHALED ABD EL-HADY ABD EL-AZHEM**

MB, BCh, M.Sc., (PATHOLOGY)

## **PRINCIPAL SUPERVISORS**

**PROF. DR. EFFAT RAMADAN EL-SHERIF**

Professor and Head of  
Pathology Department  
Faculty Of Medicine  
Cairo University



**PROF. DR. FAHIMA HABIB**

Professor of Pathology  
Faculty Of Medicine  
Cairo University

**PROF. DR. MAGDY MOURAD**

Professor of Pathology  
Faculty Of Medicine  
Cairo University

**PATHOLOGY DEPARTMENT**

**FACULTY OF MEDICINE**

**CAIRO UNIVERSITY**

**1996**

## **ACKNOWLEDGMENT**

*I would like to express my sincere gratitude and deepest appreciation to Prof. Dr. **EFFAT EL-SHERIF** Professor and Head of Pathology Department, Faculty of Medicine, Cairo University, for his generous supervisor, stimulating suggestions, Keen interest and valuable comments throughout every step in this work.*

*I would like to express my deep appreciation and profound gratitude to Prof. Dr. **FAHIMA HABIB**, Professor of Pathology, Faculty of Medicine, Cairo University for his highly valuable supervision, and constructive instructions and advises throughout this research. His remarks, criticism and great experience in this Field specifically and in Pathology generally have added much to my Knowledge.*

*I am grateful to Prof. Dr. **MAGDY MOURAD** Professor of Pathology, Faculty of Medicine Cairo University, who was very Kind saving no time or effort in helping me as her valuable comments and expert supervision enabled me to finish this work.*

*I also thank Prof. Dr. **ELIA ANIS** Professor of Pathology, Cairo University for his help, enthusiastic attitude and continuous encouragement throughout this research.*

*I extend my thank to include all members of Pathology Department, Faculty of Medicine, Cairo University. to my Family, all my thanks and love go.*

## CONTENTS

* Rational and background.....	1
* Objective.....	5
* Review of Literature.....	6
* Material and Methods.....	115
* Results.....	125
* Discussion.....	184
* Summary.....	197
* Conclusions and Recommendations.....	202
* References.....	204
* Arabic Summary.....	

*RATIONAL  
AND  
BACKGROUND*

## RATIONAL AND BACKGROUND

Incidence of endometrial cancer is increasing. standardized mortality rate per 100,000 women was 9.66 for endometrial cancer. For this reason better indices for prognosis and therapy selection are required (Key et al., 1988).

Because endometrial cancer belongs to the category of hormone dependent neoplasias, endocrine indicators such as female steroid receptors have been expected to serve a new basis for categorization of patients with endometrial cancer as far as prognosis and treatment modalities are concerned (Hoffman and Sitteri, 1980).

It is now well known that estrogen and progesterone receptors play a role in the treatment and prognosis of breast and endometrial carcinomas (Marc et al., 1992).

Estrogen receptor (ER) and progesterone receptor (PR) content of endometrial carcinomas correlate with a variety of clinicopathological parameters (Stage, histological grade, etc.) prognosis, and survival. (Palmer et al., 1988).

The progesterone receptors have only recently been studied by immunohistochemical methods (Ferenczy et al., 1989).

Receptor status of both estrogen and progesterone receptors related most strongly to histologic grade of tumor, with well differentiated tumors more likely to be receptor positive and to have a higher absolute receptor content. Similarly, a less invasive tumor was more likely to have a higher estrogen and progesterone receptor content. The relationship between low receptor content and advanced stage was significant. Quantitative rather than qualitative receptor study values in stratification of future treatment protocols to prevent their effect on survival from producing bias in results (Palmer et al., 1988).

In large tumors not only can receptor content varies across a tumor but even receptor status can varies from positive to negative across an individual tumor. The follow up of the patients indicate possible clinical significance of a heterogeneous receptor distribution across a tumor. Clinically it is not easy to determine whether an advanced local tumor is slow growing or aggressive. Multiple biopsies of such tumors for determination of functional receptor status may be useful. These tumors which are receptor positive throughout, reflect a relatively good prognosis whereas variation in receptor status across the tumor may be associated with poor prognosis. In conclusion assay of functional receptors from different parts of large endometrial cancers may be a measure of both hormone sensitivity and prognosis (Castagnetta et al., 1987).

Estrogen and progesterone are known to modulate endometrial proliferation and differentiation via their receptors. Several studies have indicated that prolonged estrogenic stimulation, unopposed by progesterone, may promote the development of endometrial hyperplasia, atypical hyperplasia, and adenocarcinoma (Key et al., 1988).

Most women with hyperplasia do not have a significantly increased risk for developing an endometrial cancer and will respond favorably to progestational thereby. In contrast, endometrial hyperplasia with cytological atypia often progresses to carcinoma and shows unfavorable response to progesterone. When endometrial adenocarcinoma has developed, the proliferation character of this disorder has become irreversible. For histopathological evaluation of endometrial atypical hyperplasia, a marker that could better identifies patients at increased risk for cancer would be very helpful and this marker might be used as a prognostic indicator for progression once adenocarcinoma has developed (Ehrlich et al., 1988, Ferenczy et al., 1989 and Palmer et al., 1988).

Hormone responsiveness of endometrial epithelium has been shown to depend strongly on interaction with the stroma, suggesting autocrine and paracrine action between these cell types. Stimulated by steroids, the stroma produces growth regulating factors which control epithelial cell differentiation and function. Such stromal-epithelial interaction may also play a role in the formation of proliferative disorders of the endometrium (Marc et al., 1992).

The presence of functional PR has been correlated with response to progestational therapy. The extensive PR staining that found in endometrial hyperplasia explains why these lesions can be brought to secretory differentiation by progestational therapy in 100% of cases. The less extensive steroid receptor immunoreactivity in endometrial atypical hyperplasia suggests that this lesion may be less sensitive to progestational therapy rather than hyperplasia (Ferenczy et al., 1989).

Endometrial hyperplasia, atypical hyperplasia and adenocarcinoma with increasing epithelial atypia are correlated with a progressive loss of steroid receptor content. Stromal cells in atypical hyperplasia and well differentiated adenocarcinoma exhibit a relative loss of PR content as compared with epithelial cells, and in atypical hyperplasia the decrease in stromal receptor content is not in parallel for ER and PR. Therefore defects in hormonal interactions between stromal and epithelial cells are associated with neoplastic transformation of endometrial proliferative lesions (Marc et al., 1992).

Many of the patients with endometrial carcinoma and hyperplasia are generally old and frequently have medical illnesses such as diabetes mellitus, obesity and hypertension. For this reason, the so called "adjuvant" hormonal therapy especially in unselected groups of patients is not entirely harmless (Ehrlich et al., 1981, and Shijders et al., 1990).

Recently, monoclonal antibodies specific for the binding with the progesterone receptors have become available. Immunohistochemistry with these monoclonal antibodies allows localization of the steroid receptors at the cellular level (Press et al., 1986).

The availability of well characterized reagents and a sensitive immunoperoxidase technique helps in detection and amplification of the few receptor molecules present in individual cells (Green and Jensen, 1982).

## OBJECTIVE

1. To find out the correlation between the most adopted standard diagnosis, criteria of progesterone responsive lesions and the progesterone receptor (PR) data assessed by immunohistochemistry.
2. To evaluate the importance of the progesterone receptor data in relation to the histopathological study of these lesions in some Egyptian patients.
3. To study the stromal hormonal receptor pattern in relation to epithelial one in these lesions.

# REVIEW